WO1995005203A1 - Method for removal of residual microbicide from a percutaneous medical device - Google Patents
Method for removal of residual microbicide from a percutaneous medical device Download PDFInfo
- Publication number
- WO1995005203A1 WO1995005203A1 PCT/US1994/007840 US9407840W WO9505203A1 WO 1995005203 A1 WO1995005203 A1 WO 1995005203A1 US 9407840 W US9407840 W US 9407840W WO 9505203 A1 WO9505203 A1 WO 9505203A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medical device
- microbicide
- percutaneous medical
- hydrogen peroxide
- percutaneous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
Definitions
- This invention relates to a method for the removal of residual microbicide from a percutaneous medical device, and more particularly to a method for the removal of residual hydrogen peroxide and peroxyacetic acid from a reprocessed percutaneous transluminal coronary angioplasty catheter.
- PTCA Percutaneous transluminal coronary angioplasty
- CATHxTM anti-corrosive microbicide
- CATHxTM or other microbicides
- CATHxTM should not be used to reprocess PTCA catheters because it is difficult to remove residual hydrogen peroxide and peroxyacetic acid solution, or other microbicides, from the closed end. If the closed end ruptures during the time the PTCA catheter is reused, residual hydrogen peroxide and peroxyacetic acid solution could be injected into the bloodstream of a patient.
- a suitable diluent such as water, saline, and the like, takes 10-20 minutes or longer.
- Conventional methods for removing residual microbicides, such as hydrogen peroxide and peroxyacetic acid, from percutaneous medical devices, such as catheters are inefficient, costly and time consuming.
- An object of the present invention is to provide a simple, fast and effective method for removing residual microbicides from a percutaneous medical device.
- a further object of the present invention is to provide a method for removing residual hydrogen peroxide and peroxyacetic acid from a reprocessed PTCA catheter.
- An embodiment of the invention relates to a method for removing residual microbicide from a percutaneous medical device comprising contacting the surfaces of the medical device with sufficient amount of a neutralizing solution to neutralize the residual microbicide, wherein the neutralizing solution and reaction products of the neutralizing solution and the microbicide are injectable into a human bloodstream.
- Another embodiment of the invention relates to a method for reprocessing a used PTCA catheter comprising removing residual hydrogen peroxide and peroxyacetic acid from the catheter by passing a sufficient amount of a neutralizing solution through the catheter to neutralize residual hydrogen peroxide and residual peroxyacetic acid, wherein the neutralizing solution and reaction products of the neutralizing solution, the hydrogen peroxide and the peroxyacetic acid are injectable into a human bloodstream.
- An embodiment of the invention relates to a method for removing residual microbicide from a percutaneous medical device comprising contacting the surfaces of the medical device with sufficient amount of a neutralizing solution to neutralize the microbicide, wherein the neutralizing solution and reaction products of the neutralizing solution and the microbicide are injectable into a human bloodstream and non-toxic to humans.
- the percutaneous medical device can be, for example, a used percutaneous medical device which has been sterilized by the microbicide and residual microbicide remains on the surfaces thereof. After removing the residual microbicide according to the present invention, the used percutaneous medical device is reprocessed and can be reused in a patient.
- Another embodiment of the invention relates to a method for reprocessing a used PTCA catheter comprising removing residual hydrogen peroxide and peroxyacetic acid from the catheter by passing a sufficient amount of a neutralizing solution through the catheter to neutralize residual hydrogen peroxide and residual peroxyacetic acid, wherein the neutralizing solution and reaction products of the neutralizing solution, the hydrogen peroxide and the peroxyacetic acid are injectable into a human bloodstream.
- the microbicide can be any conventional microbicide provided that the reaction products of the microbicide and the neutralizing solution are injectable into the human blood stream.
- the microbicide preferably includes hydrogen peroxide and peroxyacetic acid, for example, CATHxTM, the formula of which is disclosed below in Example 1.
- the microbicide can include conventional additives, for example, an anti-corrosive agent.
- the neutralizing solution reduces hydrogen peroxide to water and reduces peroxyacetic acid to acetic acid and water.
- the neutralizing solution contains, for example, an enzyme, a metal ion or ascorbic acid, which converts residual hydrogen peroxide to water and converts residual peroxyacetic acid to water and acetic acid.
- the neutralizing solution contains ascorbic acid.
- the neutralizing solution can be, for example, a sterile solution in water of 250 mg/ l of ascorbic acid along with a sufficient amount of an agent, such as sodium hydroxide, sodium carbonate or sodium bicarbonate, to adjust the pH between about 5.5 to about 7.0.
- an agent such as sodium hydroxide, sodium carbonate or sodium bicarbonate
- Ascorbic acid (vitamin C) is an effective reducing agent going from ascorbic acid to dehydroascorbic acid, as follows:
- the ascorbic acid will convert the residual hydrogen peroxide to water by the following reaction: H 2 0 2 + 2H + > 2H 2 0
- mice lethal dose for ascorbic acid in mice is 518 mg/kg and rats is 4 g-m/kg.
- the TDO tolerated dose, no effect in women is 900 mg/kg.
- the renal threshold for ascorbic acid is about 1.5 mg/dl of plasma (85 mM) and increased amounts of ascorbic acid are excreted.
- "Megadose" practices such as for preventing or curing the common cold, have shown a "rebound” scurvy phenomenon where subjects who are consuming large amounts of ascorbic acid suddenly stop consuming ascorbic acid. This is presumably due to induction of pathways of ascorbic acid metabolism as a result of the extended high dosage.
- the acetic acid formed by the reaction of residual peroxyacetic acid and ascorbic acid is at such a low concentration that no demonstratable effects are produced.
- the LD50 of acetic acid in mice is 525 mg/kg, which is greater than the level of ascorbic acid.
- the present invention can be used to reprocess a used percutaneous medical device, for example, a PTCA catheter.
- the percutaneous medical device to be reprocessed is preferably submerged in a sterile saline solution to prevent blood and contaminants on the surface thereof from drying. Preferably, excess blood and contaminants are wiped off the surface.
- the percutaneous medical device is a PTCA catheter, it is preferably flushed with saline before sterilizing.
- the percutaneous medical device is then reprocessed with a microbicide to sterilize it.
- the percutaneous medical device contains an inner space, such as the balloon on a PTCA catheter, a syringe can be used to force the microbicide into the percutaneous medical device.
- the sterilized percutaneous medical device can be stored for up to about 14 days.
- the microbicide Before the sterilized percutaneous medical device can be reused, the microbicide must be neutralized. Before neutralizing the microbicide in the percutaneous medical device, excess sterilizing solution is preferably removed from the inside of the percutaneous medical device.
- the surfaces of the sterilized percutaneous medical device are then rinsed with the neutralizing solution to neutralize the microbicide.
- a microbicide containing hydrogen peroxide such as CATHxTM
- CATHxTM a microbicide containing hydrogen peroxide
- the concentration of residual hydrogen peroxide is tested. If the concentration of hydrogen peroxide is not at a safe or non-toxic level to be injected into a human bloodstream, the percutaneous medical device is rinsed again with a fresh neutralizing solution and the concentration of hydrogen peroxide retested. This procedure is repeated until the concentration of hydrogen peroxide is safe or non-toxic for injecting into the human bloodstream, for example, less than about 440 ppm. More preferably the level of hydrogen peroxide is less than or equal to about 10 ppm.
- the preferred amount is greater than the molar equivalent of the amount of hydrogen peroxide present in the percutaneous medical device. This amount can be approximated, for example, by assuming the worst case situation.
- the worst case for a typical PTCA catheter is when the PTCA catheter has not had any CATHxTM removed before the neutralizing solution is introduced and the catheter holds the maximum volume of fluid possible, which is slightly less than lcc.
- the amount of ascorbic acid used is about 1000 mg or more to neutralize the residue in a typical PTCA catheter.
- a syringe can be used to force the ascorbic acid solution into the percutaneous medical device, such as a PTCA catheter.
- a 5 cc syringe containing the equivalent of about 2 cc of 500 mg/ml, sterile, liquid ascorbic acid can be used to flush the inside of a typical PTCA catheter having a balloon as follows.
- the syringe filled with the ascorbic acid solution can be attached to the balloon port of the catheter.
- the balloon can be, for example, inflated and deflated with the ascorbic acid solution for a total of about one minute.
- the balloon can be inflated by depressing the plunger and holding for about three seconds.
- the balloon can be deflated by withdrawing the plunger the length of the syringe and holding for three seconds. Bubbles will appear in the catheter tubing, balloon and in the syringe.
- the syringe can then be, for example, removed from the balloon port and attached to an infusion lumen port so that the ascorbic acid solution can be flushed through the lumen.
- a sterile syringe can be attached to the balloon port and a small amount of liquid withdrawn therefrom. The syringe can then be removed from the catheter and the sample of liquid within the syringe can be tested using, for example, CATHxTM Residual Test Strips (Minntech Corp., Minneapolis, MN) , to insure the liquid in the catheter contains about 10 ppm hydrogen peroxide or less.
- the CATHxTM Residual Test Strips detect inorganic or organic compounds which contain a peroxide or a hydroperoxide group.
- the test strip is dipped into the solution to be tested for about one second, to properly wet the reaction zone.
- Peroxidase contained in the reaction zone transfers oxygen from the peroxide to an organic redox indicator in the reaction zone which is converted to a blue-colored oxidation product.
- the color of the reaction zone is compared to a color scale after about 15 seconds to determine the concentration of peroxide. If any blue coloration appears within about 3 minutes, a positive reaction for peroxide has occurred.
- a sterile syringe can be attached to the infusion lumen port and a sample of the liquid can be pushed out the tip of the catheter.
- the sample can be tested using, for example, CATHxTM Residual Test Strips to insure the liquid in the lumen contains about 10 ppm hydrogen peroxide or less.
- the PTCA catheter can be reused if the hydrogen peroxide concentration is below about 440 ppm, the preferred concentration before reuse is about 10 ppm. If any part of the PTCA catheter tests above about 10 ppm it is preferably flushed again with neutralizing solution.
- the reprocessed PTCA catheter can be reused immediately after flushing with the neutralizing solution. Preferably, excess neutralizing solution is removed from the inside of the PTCA catheter before reusing.
- the neutralizing solution can be diluted with sterile saline to compensate for the increased volume of the monorail catheter so that the balloon is fully inflated during neutralization.
- the lumen of the monorail can be flushed using the catheter monorail adapter.
- the method according to present invention can be automated.
- an automated reprocessing system is disclosed which can be used to perform the method according to the present invention.
- Commonly owned Application No. 07/835,729 which is incorporated herein by this reference, discloses another reprocessing and sterilizing system that can be used to perform the method according to the present invention, which uses a unique catheter sterilizing cassette that permits storage of sterilized catheters for periods of one week to one month without breaks in sterility.
- Commonly owned Application No. 08/097,891 which is incorporated herein by this reference, discloses an adaptor so that monorail- type or rapid exchange catheters can be reprocessed, in particular in a reprocessing system of the type disclosed in the '729 application.
- Test solutions of CATHxTM were neutralized with ascorbic acid and evaluated for their potential to cause hemolysis to the blood of the rabbit.
- a pilot study and a main study were conducted.
- the susceptibility of the rabbit to a known hemolytic agent, purified water, was substantiated at NAmSA with this method.
- CATHxTM was made by mixing together part A and part B as follows:
- Part A 18% - 30% by weight hydrogen peroxide 6% - 10% by weight acetic acid 3% - 5% by weight peroxyacetic acid balance water
- Part B .1% Victawet® balance water
- the combined concentration was as follows:
- Hydrogen peroxide 0.004% - 30% by weight Acetic acid 0.025% - 12% by weight Peroxyacetic acid 0.0003% - less than 55% by weight Victawet® 0.001% - 0.1% by weight
- Victawet® comprises the following: a) 20%-45% by weight mono sodium salt of phosphoric acid, mono (2-ethyl hexyl) ester; b) 20%-30% by weight pyrophosphonic acid, bis (2-ethyl hexyl) esters, sodium salts; c) 10%-25% by weight polyphosphonic acids, 2-ethyl hexyl esters, sodium salts; d) 20%-25% by weight water; e) less than 10% by weight phosphoric acid, bis (2-ethyl hexyl) ester, sodium salt; f) less than 3% by weight 2-ethyl hexanol; and g) less than 5% by weight phosphoric acid, sodium salts, mono and di.
- the temperature was room temperature.
- CATHxTM was mixed with two parts of ascorbic acid (AA) by volume.
- AA ascorbic acid
- 10 ml of CATHxTM was mixed with 20 ml of AA
- 20 ml of CATHxTM was mixed with 40 ml AA.
- the concentration of the AA was 500 mg AA per ml of water. Each solution was tested 1 minute after mixing.
- Rabbits identified by ear tag or tattoo, were individually housed in suspended cages and received a commercially pelleted rabbit feed on a daily basis; tap water was freely available. No diet or water analysis was performed since there were no contaminants suspected that could interfere with this study. Animal husbandry and environmental conditions conformed to current NAmSA SOP's which are based on the "Guide for the Care and Use of Laboratory Animals," NIH Publication No. 85-23.
- the dose of the main study was set at 3 ml/rabbit.
- the test solution was then slowly injected intravenously via the marginal ear vein into each of two rabbits at the prescribed dose.
- test solution was not considered hemolytic. There was no increase in plasma iron between the pre and posttreatment determinations.
- NAmSA test data was based on agarose overlay of L-929 mouse fibroblast cells. Levels tested included a 1:300 and a 1:200 dilution of the mixed, ready to use Cathx. The 1:200 level was toxic, the 1:300 was not.
- Viromed test data was based on agarose overlay of L-929 mouse fibroblast cells. Levels tested were 1:200, 1:220, 1:240, 1:260, 1:280, 1:300 and 1:400 dilution of the mixed, ready to use CATHxTM. The 1:280 level was toxic, the 1:300 was not. The applicants believe to the best of their ability that NAmSA followed the same test procedures as VIROMED which were as follows.
- the above cytotoxicity assay was designed to screen the biological reactivity of mammalian cell cultures following contact by diffusion of leachable, cytotoxic chemicals in materials or formulations.
- the L-929 cell line has a significant history of use in assays of this type.
- E- MEM Eagle's minimal essential medium
- fbs heat inactivated fetal bovine serum
- the medium may also be supplemented with glutamine (2mM) and one or more of the following antibiotics: gentamicin (50 ug/ l) , penicillin (100 units/ml), amphotericin B (2.5 ug/ml) .
- Cultures were maintained and used as monolayers in 60mm diameter tissue culture plates at 37°C in a humidified atmosphere of 5% CO in air.
- Agar overlay medium contained E-MEM with 2mM glutamine, not more than 2% agarose, 2-5% fbs, and one or more of the antibiotics described above.
- Alternative Cell Lines include:
- WI-38 human embryonic lung propagated and maintained on E-MEM with 10% fbs and antibiotics
- MRC-5 human embryonic lung propagated and maintained on E-MEM with 10% fbs and antibiotics.
- the size of the article to be tested was determined by the following ASTM guidelines: 1. Liquids or extracts will be prepared by saturating each sterile noncytopathic filter disk (Millipore AP2501000) with 0.1 ml aliquot.
- test article is sufficiently small to fit into the culture dish leaving an adequate margin of cells for evaluation, the entire article will be used.
- test article(s) and controls were placed on the agarose surface of the test plates. A cell control plate was run concurrently. The plates were incubated at 37°C in 5% C0ont for 24 ⁇ l hours.
- Zone index is a measure of area affected by the test article based upon visual observation of neutral red uptake.
- Zones limited to area under specimen. 3 Zone extends 0.5 - 1.0 cm beyond specimen. 4 Zone extends greater than 1.0 cm beyond specimen.
- the above Viromed test procedure is published in U.S. Pharmacopeia U.S.P. XXII, 5th Supplement, page 2702 (U.S.P. 1991) which is incorporated herein by this reference.
- Cidex7 is a reusable sterilizing and disinfecting solution containing 2.0% glutaraldehyde as the active ingredient. The final use dilution was tested. The results were as follows: dilution tested result
- CATHxTM A production lot of CATHxTM was taken to BETEC Laboratory (Minneapolis, MN) to be tested for hydrogen peroxide. After mixing part A and part B in the same manner as in Example 1, one ml of the freshly mixed CATHxTM was tested for hydrogen peroxide using the UPS XXII, spot test with K 2 Cr 2 0 7 , which is published in U.S. Pharmacopeia U.S.P. XXII, 5th Supplement, (U.S.P. 1991) , which is incorporated herein by this reference. The CATHxTM gave a strong positive test for hydrogen peroxide. A one ml sample of this freshly made solution was mixed with one ml of an ascorbic acid solution containing 500 mg/ml ascorbic acid.
- the ascorbic acid used was ascorbic acid injection USP 500mg/ml McGuff Company lot 2601 MG expiration date 10/94, containing no preservative.
- Rabbits identified by ear tag or tattoo, were individually housed in suspended cages and received a commercially pelleted rabbit feed on a daily basis; tap water was freely available. No diet or water analysis was performed since there were no contaminants suspected that could interfere with this study. Animal husbandry and environmental conditions conformed to current NAmSA SOP which are based on the "Guide for the Care and Use of Laboratory Animals," NIH Publication No. 85-23.
- Each rabbit was weighed and anesthetized by intramuscular injection of a combination of ketamine hydrochloride/xylazine (34 mg/kg + 5 mg/kg) at a dose of 0.6 ml/kg.
- the animals were then placed on halothane/oxygen inhalation for continued general anesthesia during the procedure.
- a blood sample was collected from each animal prior to dosing. Animals were then connected to the electrocardiograph and a pretreat tracing (ECG) of cardiac activity was obtained.
- ECG pretreat tracing
- Each animal was injected intra-arterially via the middle ear artery with the designated material using a 20 gauge needle as follows:
- Ascorbic acid 4.0 ml 250 mg/ml concentration
- An ECG tracing of cardiac performance was obtained before, during and after dosing. Intervals for postdose tracings were varied and at the discretion of the staff veterinarian.
- a blood sample was collected from each animal prior to dosing and from surviving animals at approximately 24 hours after dosing. Animals were anesthetized prior to the blood draw. The pretreatment blood draw was obtained from the central ear artery while the postdose draw was from the abdominal aorta or posterior vena cava. Blood samples were allowed to clot and then centrifuged to obtain serum. Half the serum for each sample was frozen and half was kept at room temperature. At approximately 24 hours after dosing, surviving animals were anesthetized and exsanguinated following blood draw. Macroscopic observations of the viscera, including the heart, were conducted on these or any animal found dead before this interval. The heart and ears of all euthanatized animals were excised and placed in 10% neutral buffered formalin. The heart was retained from animals that died.
- Serum sample analyses were conducted by Roche Bioveterinary Services (Division of Roche Biomedical Laboratories, Inc.). The evaluation entailed enzyme testing for creatine kinase (“CPK”) , lactic acid dehydrogenase (“LDH”) and isoenzymes of each.
- CPK creatine kinase
- LDH lactic acid dehydrogenase
- the ears from animals in Groups 2, 4, and 6 were chosen by the sponsor for histopathology. A cross section of the ears through the blood vessels were routinely embedded in paraffin, cut, and stained in hematoxylin and eosin. Microscopic evaluation was then conducted by R.F. McConnell, D.V.M. , a board certified veterinary pathologist.
- the group 4 animals dosed with 2.0 ml CATHx appeared much the same as Group 1 animals except lethargy was more severe, salivation was observed, and chemosis was noted for the nictitating membrane of the eye located on the same side as the injected ear.
- the group 5 animal exhibited abnormal respiration and discomfort upon injection of the ascorbic acid; otherwise the rabbit appeared normal.
- the group 6 animal exhibited abnormal respiration upon injection of the CATHx/ascorbic acid mixture; otherwise the animal appeared normal.
- the group 8 animal exhibited abnormal respiration and discomfort upon injection of the mixture of CATHx, ascorbic acid, saline and contrast media; otherwise the rabbit appeared normal.
- CPK creatine phosphokinase
- LDH lactic dehydrogenase ⁇
- the data in Table VI illustrates that ascorbic acid dramatically reduces gas evolution from CATHx after contact with blood.
- Gold Myochrysine
- platinum platinum
- Both gold and platinum compounds had significantly more gas evolution after mixing with blood and CATHxTM than blood, CATHxTM, and ascorbic acid and about the same volume of gas evolution as blood, CATHxTM, and saline.
- the data in Table VI also illustrates that there is a relationship to gas generation and the ratio of ascorbic acid to CATHxTM . In the test situation, a plateau of decreasing gas evolution seems to be reached at a 1.0 ml CATHxTM to a 1.0 ml (500mg/ml) ascorbic acid with no further obvious decrease in gas evolution above this point.
- Table VI further illustrates that the addition of catalase to a blood/CATHx/ascorbic acid mix does not cause an increase in gas evolution above that seen by adding blood to a CATHx/ascorbic acid mix.
- Table VI The data in Table VI is presented as gas generated just before mixing and just before mixing to give an indication of the reactivity of the system prior to mixing (a "system blank") .
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU73313/94A AU694440B2 (en) | 1993-08-16 | 1994-07-13 | Method for removal of residual microbicide from a percutaneous medical device |
BR9406855A BR9406855A (en) | 1993-08-16 | 1994-07-13 | Process for removing residual microbicide from a percutaneous surgical device |
KR1019960700814A KR960703626A (en) | 1993-08-16 | 1994-07-13 | METHOD FOR REMOVAL OF RESIDUAL MICROBICIDE FROM A PERCUTANEOUS MEDICAL DEVICE |
EP94923448A EP0714309A1 (en) | 1993-08-16 | 1994-07-13 | Method for removal of residual microbicide from a percutaneous medical device |
JP7506950A JPH08508916A (en) | 1993-08-16 | 1994-07-13 | Method for removing residual microbicides from percutaneous medical devices |
NO960596A NO960596D0 (en) | 1993-08-16 | 1996-02-15 | Method of removing residual microbicide from a percutaneous medical device |
FI960686A FI960686A (en) | 1993-08-16 | 1996-02-15 | A method of removing a microbicide residue from a percutaneous medical device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10698593A | 1993-08-16 | 1993-08-16 | |
US08/106,985 | 1993-08-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995005203A1 true WO1995005203A1 (en) | 1995-02-23 |
Family
ID=22314261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/007840 WO1995005203A1 (en) | 1993-08-16 | 1994-07-13 | Method for removal of residual microbicide from a percutaneous medical device |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0714309A1 (en) |
JP (1) | JPH08508916A (en) |
KR (1) | KR960703626A (en) |
AU (1) | AU694440B2 (en) |
BR (1) | BR9406855A (en) |
CA (1) | CA2165184A1 (en) |
FI (1) | FI960686A (en) |
NO (1) | NO960596D0 (en) |
WO (1) | WO1995005203A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830409A (en) * | 1996-01-04 | 1998-11-03 | American Sterilizer Company | Method to shorten aeration after a sterilization cycle |
US7601731B2 (en) | 2003-06-06 | 2009-10-13 | Board Of Regents, The University Of Texas System | Antimicrobial flush solutions |
US7651661B2 (en) | 2001-01-12 | 2010-01-26 | Board Of Regents, The University Of Texas System | Medical devices with broad spectrum antimicrobial activity |
US10589003B2 (en) | 2005-11-18 | 2020-03-17 | The Board Of Regents Of The University Of Texas System | Methods for coating surfaces with antimicrobial agents |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009154302A1 (en) * | 2008-06-19 | 2009-12-23 | 株式会社聖蹟ミリオラブルー | Water supply unit for use in sterilizing and cleaning system using sterile water |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4368081A (en) * | 1980-09-05 | 1983-01-11 | Jujo Paper Co., Ltd. | Method for removing residual hydrogen peroxide on a sterilized food package |
US4721123A (en) * | 1986-10-23 | 1988-01-26 | Minntech Corporation | Catheter reprocessing system |
US4986963A (en) * | 1989-01-24 | 1991-01-22 | Corcoran Richard A | Method of disinfecting contact lenses with peracetic acid |
WO1992011042A1 (en) * | 1990-12-19 | 1992-07-09 | Allergan, Inc. | Compositions and methods for contact lens disinfecting |
US5310524A (en) * | 1992-02-11 | 1994-05-10 | Minntech Corporation | Catheter reprocessing and sterilizing system |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4521375A (en) * | 1982-11-23 | 1985-06-04 | Coopervision, Inc. | Sterilizing treatment with hydrogen peroxide and neutralization of residual amounts thereof |
FR2578332B1 (en) * | 1985-01-30 | 1989-03-31 | Air Liquide | ASEPTISAN COMPOSITION FOR CONTACT LENSES |
US4829001A (en) * | 1985-11-08 | 1989-05-09 | Minnesota Mining And Manufacturing Company | Enzymatic neutralization of hydrogen peroxide |
JPH07112489B2 (en) * | 1989-06-26 | 1995-12-06 | エフ エム シー コーポレーション | Hydrogen peroxide, peracid and U.S. V. Sterilization of containers by irradiation |
-
1994
- 1994-07-13 KR KR1019960700814A patent/KR960703626A/en not_active Application Discontinuation
- 1994-07-13 AU AU73313/94A patent/AU694440B2/en not_active Ceased
- 1994-07-13 BR BR9406855A patent/BR9406855A/en not_active Application Discontinuation
- 1994-07-13 CA CA002165184A patent/CA2165184A1/en not_active Abandoned
- 1994-07-13 WO PCT/US1994/007840 patent/WO1995005203A1/en not_active Application Discontinuation
- 1994-07-13 EP EP94923448A patent/EP0714309A1/en not_active Withdrawn
- 1994-07-13 JP JP7506950A patent/JPH08508916A/en active Pending
-
1996
- 1996-02-15 NO NO960596A patent/NO960596D0/en unknown
- 1996-02-15 FI FI960686A patent/FI960686A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4368081A (en) * | 1980-09-05 | 1983-01-11 | Jujo Paper Co., Ltd. | Method for removing residual hydrogen peroxide on a sterilized food package |
US4721123A (en) * | 1986-10-23 | 1988-01-26 | Minntech Corporation | Catheter reprocessing system |
US4986963A (en) * | 1989-01-24 | 1991-01-22 | Corcoran Richard A | Method of disinfecting contact lenses with peracetic acid |
WO1992011042A1 (en) * | 1990-12-19 | 1992-07-09 | Allergan, Inc. | Compositions and methods for contact lens disinfecting |
US5310524A (en) * | 1992-02-11 | 1994-05-10 | Minntech Corporation | Catheter reprocessing and sterilizing system |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830409A (en) * | 1996-01-04 | 1998-11-03 | American Sterilizer Company | Method to shorten aeration after a sterilization cycle |
US7651661B2 (en) | 2001-01-12 | 2010-01-26 | Board Of Regents, The University Of Texas System | Medical devices with broad spectrum antimicrobial activity |
US7601731B2 (en) | 2003-06-06 | 2009-10-13 | Board Of Regents, The University Of Texas System | Antimicrobial flush solutions |
US8709342B2 (en) | 2003-06-06 | 2014-04-29 | Board Of Regents, The University Of Texas System | Antimicrobial flush solutions |
US9078441B2 (en) | 2003-06-06 | 2015-07-14 | Board Of Regents, The University Of Texas System | Antimicrobial flush solutions |
US10589003B2 (en) | 2005-11-18 | 2020-03-17 | The Board Of Regents Of The University Of Texas System | Methods for coating surfaces with antimicrobial agents |
Also Published As
Publication number | Publication date |
---|---|
KR960703626A (en) | 1996-08-31 |
CA2165184A1 (en) | 1995-02-23 |
AU7331394A (en) | 1995-03-14 |
FI960686A0 (en) | 1996-02-15 |
BR9406855A (en) | 1996-03-26 |
JPH08508916A (en) | 1996-09-24 |
EP0714309A1 (en) | 1996-06-05 |
FI960686A (en) | 1996-02-15 |
NO960596L (en) | 1996-02-15 |
AU694440B2 (en) | 1998-07-23 |
NO960596D0 (en) | 1996-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Quastel et al. | Narcosis and oxidations of the brain | |
Jevtovic-Todorovic et al. | Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits | |
Fenn et al. | Effects of carbon dioxide inhalation on potassium liberation from the liver | |
Welles et al. | Preclinical toxicology studies with tobramycin | |
Caflisch et al. | Direct evaluation of acidification by rat testis and epididymis: role of carbonic anhydrase | |
Bush et al. | Physiologic measures of nonhuman primates during physical restraint and chemical immobilization | |
Karelová et al. | Chromosome and sister-chromatid exchange analysis in peripheral lymphocytes, and mutagenicity of urine in anesthesiology personnel | |
Yoshida et al. | Brain and tissue distribution of polyethylene glycol-conjugated superoxide dismutase in rats. | |
Hunter et al. | An evaluation of gamma-hydroxybutyric acid in paediatric practice | |
AU694440B2 (en) | Method for removal of residual microbicide from a percutaneous medical device | |
Kligerman et al. | Sister-chromatid exchange induction in peripheral blood lymphocytes of rats exposed to ethylene oxide by inhalation | |
Graeber et al. | Elevated levels of peripheral serum creatine phosphokinase with strangulated small bowel obstruction | |
Murray et al. | Plasma fluoride concentrations during and after prolonged anesthesia: a comparison of halothane and isoflurane | |
Custer et al. | Hematologic effects of xylazine when used for restraint of Bactrian camels | |
Hayes | Essays in Toxicology: Volume 6 | |
Wollin et al. | Plasma protein escape from the intestinal circulation to the lymphatics during fat absorption | |
Sakai et al. | Vascularly perfused rat small intestine: a research model for drug absorption | |
Sanders | Use of a radioactive gas (Kr85) in diagnosis of cardiac shunts. | |
Chen et al. | Species variation in pulmonary endothelial aminopeptidase P activity. | |
Abreu et al. | Susceptibility to Ether Anesthesia of Mice Habituated to Alcohol, Morphin or Cocain. | |
Susić et al. | Attenuation by arachidonic acid of the effect of vasoconstrictor stimuli in the canine kidney. | |
Waddell et al. | The practitioner’s acid-base primer: obtaining & interpreting blood gases | |
Coran | The effect of lactated ringer's solution on blood and urine levels of lactate isomers | |
Gordon et al. | Toluene diisocyanate-induced airway injury in guinea pigs | |
Gumbleton et al. | Possible hemodynamic basis to urethane anesthesia-induced reductions in renal clearance. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2165184 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 960686 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994923448 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994923448 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994923448 Country of ref document: EP |